secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0000950170-24-014919
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics terminates at-the-market equity facility with Guggenheim; no shares ever sold
--------------------------------------------------------------------------------

- Terminated Sales Agreement with Guggenheim Securities effective Feb 13, 2024.
- Agreement permitted up to $50M in at-the-market common stock offerings.
- No shares of common stock were ever sold under the agreement.
- Original agreement date was November 10, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/0000950170-24-014919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024014919/lrmr-20240213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-014919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer